Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service pacemaker, ICD & CRT implantation cases in Nebraska: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (249 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 24 | 1,693 | 18% |
| 2020 | 22 | 1,495 | 22% |
| 2021 | 23 | 1,526 | 27% |
| 2022 | 24 | 1,443 | 31% |
| 2023 | 26 | 1,528 | 35% |
| 2024 | 20 | 1,389 | 37% |
| 2025 from claims | – | 1,338 1,225–1,420 | 37% |
| 2026 forecast | – | 1,361 1,198–1,565 | 37% |
| 2027 forecast | – | 1,376 1,177–1,631 | 37% |
| 2028 forecast | – | 1,390 1,161–1,693 | 38% |
| 2029 forecast | – | 1,405 1,148–1,751 | 38% |
| 2030 forecast | – | 1,419 1,138–1,806 | 38% |
Pacemaker, leadless, ICD, S-ICD, CRT, and generator replacements. Professional codes (what the surgeon bills): CPT 33206, 33207, 33208, 33274, 33249, 33270, 33262, 33263, 33264; the hospital bills MS-DRG 242, 243, 244, 226, 227, 275, 276, 277.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 82% of the cases CMS names in Nebraska; 10 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 37% inpatient hospital, 59% hospital outpatient, 4% surgery center.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Surgery center |
|---|---|---|---|
| 2026 · ~1,400 | ~510 | ~800 | ~54 |
| 2027 · ~1,400 | ~520 | ~800 | ~56 |
| 2028 · ~1,400 | ~530 | ~810 | ~57 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: hospital outpatient about 58% (59% in 2025).
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Illinois | 127 | 6,709−0.7%/yr | −0.7%/yr | 5.0 | 4% | 6,540 in 2030−0.4%/yr |
| Ohio | 116 | 5,341−4.9%/yr | −4.9%/yr | 5.0 | 0% | 5,510 in 2030+0.5%/yr |
| Michigan | 80 | 4,353−7%/yr | −7%/yr | 5.4 | 1% | 3,930 in 2030−1.7%/yr |
| Indiana | 79 | 4,125−1.9%/yr | −1.9%/yr | 6.1 | 0% | 4,280 in 2030+0.6%/yr |
| Missouri | 69 | 3,708−3.1%/yr | −3.1%/yr | 6.2 | 1% | 3,910 in 2030+0.9%/yr |
| Minnesota | 54 | 2,677−1.9%/yr | −1.9%/yr | 6.2 | 2% | 3,620 in 2030+5.2%/yr |
| Wisconsin | 51 | 2,523−2.6%/yr | −2.6%/yr | 4.7 | 0% | 2,860 in 2030+2.1%/yr |
| Kansas | 48 | 2,334−5%/yr | −5%/yr | 5.9 | 13% | 2,480 in 2030+1%/yr |
| Iowa | 34 | 1,667−1.9%/yr | −1.9%/yr | 3.9 | 0% | 1,710 in 2030+0.5%/yr |
| South Dakota | 8 | 590−1.5%/yr | −1.5%/yr | 4.7 | 0% | 750 in 2030+4.1%/yr |
| North Dakota | 10 | 559−1.6%/yr | −1.6%/yr | 5.8 | 0% | 640 in 2030+2.2%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| LAA occlusion & loop recorders | 22 | 1,069+16%/yr | +16%/yr | 3.71.2× | 3% | 1,720 in 2030+8.3%/yr |
| EP ablation | 15 | 802+7.1%/yr | +7.1%/yr | 2.80.9× | 0% | 1,570 in 2030+12%/yr |
Pacemaker, ICD & CRT implantation in every state, and its device makers · Every procedure market in Nebraska · Every state · Compare with Illinois
Abbott leads with 31% of company spending on these surgeons in 2025, −50 pts on 2024.
In 2025, 8 companies reported engagement with Nebraska’s surgeons worth $60K in consulting, speaking, meals and travel tied to these products, about $3,009 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 334 clearances and approvals in the category, 3 recalled product lines (2 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.